Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576431 | 1.00 | AKR1B1 (0.48) | AKR1B1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2978394 | 0.89 | CALM1 (0.51) | CALM1 | |
| SCHEMBL24201448 | 0.84 | AKR1B1 (0.49) | AKR1B1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2970029 | 0.81 | STAT3 (0.57) | CALM1 | |
| SCHEMBL29684134 | 0.81 | STAT3 (0.57) | CALM1 | |
| SCHEMBL29684225 | 0.81 | ADRB2 (0.58) | PTPN1 | |
| SCHEMBL2969158 | 0.81 | ADRB2 (0.58) | PTPN1 | |
| SCHEMBL2976580 | 0.80 | TUBB4A (0.52) | — | |
| SCHEMBL29684602 | 0.80 | TUBB4A (0.52) | — | |
| SCHEMBL2975079 | 0.78 | TTR (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259764-B2 | Series of skin whitening (lightening) compounds | UNIGEN, INC. (US) | 2019-04-16 | — | — | US | claimed |
| US-20170275224-A1 | Series of Skin Whitening (Lightening) Compounds | UNIGEN, INC. (US) | 2017-09-28 | — | — | US | claimed |
| EP-2323612-A1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | Unigen, Inc. (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010011630-A1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | UNIGEN PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | claimed |
| US-20100016347-A1 | SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS | UNIGEN PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | claimed |
| US-12227472-B2 | Series of skin-whitening (lightening) compounds | UNIGEN, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230399282-A1 | Series of Skin-Whitening (Lightening) Compounds | UNIGEN, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399282-A1 | Series of Skin-Whitening (Lightening) Compounds | UNIGEN, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399282-A1 | Series of Skin-Whitening (Lightening) Compounds | UNIGEN, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-11739040-B2 | Series of skin-whitening (lightening) compounds | UNIGEN, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739040-B2 | Series of skin-whitening (lightening) compounds | UNIGEN, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739040-B2 | Series of skin-whitening (lightening) compounds | UNIGEN, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-8362305-B2 | Series of skin whitening (lightening) compounds | UNIGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362305-B2 | Series of skin whitening (lightening) compounds | UNIGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2323612-A1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | Unigen, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010011630-A1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | UNIGEN PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011630-A1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | UNIGEN PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100016347-A1 | SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS | UNIGEN PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016347-A1 | SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS | UNIGEN PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016347-A1 | SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS | UNIGEN PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739040-B2 | Series of skin-whitening (lightening) compounds | TYR, TH, MAOB | AKR1B1 454/4885GABRA1 3729/4885GABRG2 3214/4885 |
| US-20230399282-A1 | Series of Skin-Whitening (Lightening) Compounds | TYR, TH, MAOB | AKR1B1 454/4885GABRA1 3729/4885GABRG2 3214/4885 |
| US-20170275224-A1 | Series of Skin Whitening (Lightening) Compounds | TYR, MAOB, TH | AKR1B1 508/4885GABRA1 3691/4885GABRG2 3343/4885 |
| US-20100016347-A1 | SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS | TYR, MAOB, TH | AKR1B1 508/4885GABRA1 3691/4885GABRG2 3343/4885 |
| US-10259764-B2 | Series of skin whitening (lightening) compounds | TYR, MAOB, TH | AKR1B1 508/4885GABRA1 3691/4885GABRG2 3343/4885 |
| US-12227472-B2 | Series of skin-whitening (lightening) compounds | TYR, TH, MAOB | AKR1B1 454/4885GABRA1 3729/4885GABRG2 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.